A Study of the Effect of Selective Estrogen Receptor Modulators on Pubertal Gynecomastia and Mastalgia: A Systematic Review
Rattachement africain : ir. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Objectives: Gynecomastia and mastalgia are the most typical clinical breast conditions. This systematic review aims to assess the effect of selective estrogen receptor modulators (SERMs) on pubertal gynecomastia and mastalgia. Methods: In this review study, online English databases such as PubMed, Scopus, Web of Science, and Cochrane Library were systematically searched without a time limit until January 10, 2025. Results: Tamoxifen and centchroman are both more effective than placebo in relieving breast pain. Centchroman can reduce the severity of mastalgia by 92-100%. Pain score significantly reduced in the centchroman group compared to the placebo group (P < 0.0001). Centchroman and tamoxifen similarly affected pain relief (P < 0.005). Tamoxifen was more effective than danzol in relieving breast pain (P < 0.001). The effects of tamoxifen were not dose dependent, as 10 mg and 20 mg did not follow a trend, but 10 mg produced significantly fewer side effects. There are inconsistent results when comparing the efficacy of danazol and centchroman at 12 weeks. However, tamoxifen outperformed danazol long-term AT 24 weeks. Four case series were included in the systematic review. Tamoxifen and raloxifene may be effective for the treatment of pubertal gynecomastia. In the first, reduction in breast nodule diameter was 86% in the tamoxifen group and 91%in the raloxifene group. However, a more significant improvement was observed in the tamoxifen group than in the raloxifene group (P = 0.03). In the second study, both groups had a statistically significant breast size reduction (tamoxifen group, P = 0.013; no treatment group, P = 0.038). In the third and fourth studies, the treatment success rate with tamoxifen was calculated to be 86 to 94%. Conclusions: Mild cyclic mastalgia can be treated by making appropriate lifestyle changes. Moderate to severe mastalgia usually requires medical treatment. Ormeloxifene, tamoxifen, and danazol were all effective in relieving breast pain. Tamoxifen and raloxifene may be effective for the treatment of pubertal gynecomastia.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- A Study of the Effect of Selective Estrogen Receptor Modulators on Pubertal Gynecomastia and Mastalgia: A Systematic Review
- Date Crossref
- 10/09/2025
- Éditeur
- Maad Rayan Publishing Company
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
University of Hormozgan pays non établi dans la noticeUniversité ou école supérieure
-
Zabol University of Medical Sciences Department of Pediatrics pays non établi dans la noticeUniversité ou école supérieure
-
Hormozgan University of Medical Sciences Endocrinology and Metabolism Research Center pays non établi dans la noticeUniversité ou école supérieure
-
University of Jiroft pays non établi dans la noticeUniversité ou école supérieure
-
Iranshahr University pays non établi dans la noticeUniversité ou école supérieure
-
Shahid Beheshti University of Medical Sciences pays non établi dans la noticeUniversité ou école supérieure
-
Kerman University of Medical Sciences Reproductive and Family Health Research Center pays non établi dans la noticeUniversité ou école supérieure
-
Islamic Azad University Department of Nursing and Midwifery pays non établi dans la noticeUniversité ou école supérieure
-
Faculty of Medicine Department of Obstetrics and Gynecology pays non établi dans la noticeUniversité ou école supérieure
-
School of Nursing and Midwifery Student Research Committee pays non établi dans la noticeUniversité ou école supérieure
University of Hormozgan, Department of Pediatrics — Zabol University of Medical Sciences et Endocrinology and Metabolism Research Center — Hormozgan University of Medical Sciences, avec 7 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.